Role of dopamine in learning and memory - Implications for the treatment of cognitive dysfunction in patients with Parkinson's disease

Authors
Citation
J. Kulisevsky, Role of dopamine in learning and memory - Implications for the treatment of cognitive dysfunction in patients with Parkinson's disease, DRUG AGING, 16(5), 2000, pp. 365-379
Citations number
186
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
DRUGS & AGING
ISSN journal
1170229X → ACNP
Volume
16
Issue
5
Year of publication
2000
Pages
365 - 379
Database
ISI
SICI code
1170-229X(200005)16:5<365:RODILA>2.0.ZU;2-8
Abstract
Along with dementia, Parkinson's disease (PD) is associated with subtle but widespread cognitive impairment even in the absence of clinically apparent cognitive decline. Many of the deficits are reminiscent of those observed in patients with lesions of the prefrontal cortex, that is, failure in exec utive function that involves skills required for anticipation, planning, in itiation and monitoring of goal-directed behaviours. This paper reviews the dopaminergic brain circuitry, and preclinical and clinical evidence suppor ting the regulation of prefrontal cortex activity by dopamine, and the role of dopamine in cognitive impairment in patients with PD. It addresses the need to integrate these facts and the findings of positive, neutral or detr imental frontal cognitive response to dopaminergic drugs in PD which should be viewed mainly in the context of methodological differences for subject selection. The cognitive effect of levodopa does not much depend on a neuropsychologic al specificity of the drug, the years of evolution of the disease or the se verity of the motor signs. Instead, it may be a function of the level of do pamine depletion in different parts of the basal ganglia and prefrontal cor tex. Consequently, dopaminergic agents may enhance cognitive functions in s ome patients and impair them in others. De novo patients tend to improve du ring the first year of treatment; stable responders to oral levodopa tend t o show no changes, and wearing-off responders tend to deteriorate with acut e levodopa challenge. Enhancement and impairment of cognitive function with dopaminergic treatment is incomplete and task-specific, suggesting the nee d to integrate the above dopamine facts with other neurotransmitter systems findings in PD. Meanwhile, such cognitive dissociation can be useful in re fining the definition of the cognitive deficit in PD patients without demen tia and emphasising the need to develop new and specific strategies for tre atment.